Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.
The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope.
Roche subsidiary Genentech received $209.5 million in unnecessary payments from Novartis Pharma for a patent licensing deal and is now refusing to return the payment, the Swiss pharma giant has alleged in a redacted complaint.
On June 1, 2021, the Chinese government implemented crucial changes to its patent laws, hoping to create better protections for national and international inventors.
Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.
Law firm Barnes & Thornburg has announced the opening of a Boston office, its twentieth in the US, with six partners.
A Warrington-based distributor of aesthetic and cosmetic products has lost its UK trademark for a dermal filler brand after the English High Court found it to have registered the brand in bad faith.
Supplementary protection certificates outlive medicinal patents in more than nine in ten cases, a new report has found.
Taiwanese pharmaceutical company PharmaEssentia Corporation has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals.